Loading...

Alexander Vezeridis

TitleResident Physician
InstitutionUniversity of California San Diego
DepartmentRadiology
Address200 W. Arbor Drive #8756
San Diego CA 92103
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Lyshchik A, Kono Y, Dietrich CF, Jang HJ, Kim TK, Piscaglia F, Vezeridis A, Willmann JK, Wilson SR. Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group. Abdom Radiol (NY). 2018 Apr; 43(4):861-879. PMID: 29151131.
      View in: PubMed
    2. Lux J, Vezeridis AM, Hoyt K, Adams SR, Armstrong AM, Sirsi SR, Mattrey RF. Thrombin-Activatable Microbubbles as Potential Ultrasound Contrast Agents for the Detection of Acute Thrombosis. ACS Appl Mater Interfaces. 2017 Nov 01; 9(43):37587-37596. PMID: 28994575.
      View in: PubMed
    3. Kim TK, Noh SY, Wilson SR, Kono Y, Piscaglia F, Jang HJ, Lyshchik A, Dietrich CF, Willmann JK, Vezeridis A, Sirlin CB. Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT/MRI system. Clin Mol Hepatol. 2017 Dec; 23(4):280-289. PMID: 28911220.
      View in: PubMed
    4. Kono Y, Lyshchik A, Cosgrove D, Dietrich CF, Jang HJ, Kim TK, Piscaglia F, Willmann JK, Wilson SR, Santillan C, Kambadakone A, Mitchell D, Vezeridis A, Sirlin CB. Contrast Enhanced Ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADSĀ®): the official version by the American College of Radiology (ACR). Ultraschall Med. 2017 Jan; 38(1):85-86. PMID: 28249328.
      View in: PubMed
    5. Huang Y, Vezeridis AM, Wang J, Wang Z, Thompson M, Mattrey RF, Gianneschi NC. Polymer-Stabilized Perfluorobutane Nanodroplets for Ultrasound Imaging Agents. J Am Chem Soc. 2017 01 11; 139(1):15-18. PMID: 28032757.
      View in: PubMed
    6. Vezeridis AM, Bae DS. Evaluation of Knee Donor and Elbow Recipient Sites for Osteochondral Autologous Transplantation Surgery in Capitellar Osteochondritis Dissecans. Am J Sports Med. 2016 Feb; 44(2):511-20. PMID: 26712891.
      View in: PubMed
    7. Tavri S, Vezeridis A, Cui W, Mattrey RF. In Vivo Transfection and Detection of Gene Expression of Stem Cells Preloaded with DNA-carrying Microbubbles. Radiology. 2015 Aug; 276(2):518-25. PMID: 25811427; PMCID: PMC4521611.
    8. Fotakis P, Vezeridis A, Dafnis I, Chroni A, Kardassis D, Zannis VI. apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL. J Lipid Res. 2014 Jul; 55(7):1310-23. PMID: 24776540; PMCID: PMC4076092.
    9. Koupenova M, Johnston-Cox H, Vezeridis A, Gavras H, Yang D, Zannis V, Ravid K. A2b adenosine receptor regulates hyperlipidemia and atherosclerosis. Circulation. 2012 Jan 17; 125(2):354-63. PMID: 22144568; PMCID: PMC3265935.
    10. Georgiadou D, Chroni A, Vezeridis A, Zannis VI, Stratikos E. Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia. PLoS One. 2011; 6(11):e27037. PMID: 22069485; PMCID: PMC3206067.
    11. Vezeridis AM, Chroni A, Zannis VI. Domains of apoE4 required for the biogenesis of apoE-containing HDL. Ann Med. 2011 Jun; 43(4):302-11. PMID: 21604997; PMCID: PMC3110089.
    12. Vezeridis AM, Drosatos K, Zannis VI. Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4. J Lipid Res. 2011 Jan; 52(1):45-56. PMID: 20861163; PMCID: PMC2999928.
    13. Zannis VI, Koukos G, Drosatos K, Vezeridis A, Zanni EE, Kypreos KE, Chroni A. Discrete roles of apoA-I and apoE in the biogenesis of HDL species: lessons learned from gene transfer studies in different mouse models. Ann Med. 2008; 40 Suppl 1:14-28. PMID: 18246469.
      View in: PubMed